Hymovis Hyadd 4 24mg/2x3ml

Hymovis HYADD 4 24mg, 2x3ml is a breakthrough technology in the treatment of osteoarthritis. MO.RE technology (MObile Reticulum): the molecules of hyaluronic acid contained in the Hymovis preparation have a unique three-dimensional structure and form a kind of a moving mesh (MObile Reticulum), which has the ability to completely restore flexibility and elasticity, even after repeated deformations.

HYMOVIS is a sterile, non-pyrogenic hydrogel produced with Hyadd4 (high purity hexadecylamide, natural sodium hyaluronate obtained by bacterial fermentation) in an isotonic buffer solution. Due to the high viscosity and elasticity imparted to it by sodium hyaluronate hexadecylamide, HYMOVIS improves the function of hydration and shock absorption by synovial fluid, protecting cartilage and soft tissues from mechanical damage. These properties, together with the prolonged residence time in the joints, mean that HYMOVIS brings pain relief and improves joint function with short-term treatment.

Main ingredient:

Hyadd4 (sodium hyaluronate hexadecylamide), 24mg / 3ml.

Other ingredients: sodium chloride, disodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, water for injections.

HYMOVIS is for intra-articular injection only. The product may only be administered by qualified physicians. The treatment cycle is two injections one week apart. Due to its viscosity, HYMOVIS should be injected slowly into the affected joint using a suitable sterile needle (18 or 20 gauge). Aseptic and administration techniques must be strictly followed. Avoid treatment in the event of visible symptoms of acute joint inflammation.

Joint exudate should be removed prior to injection of HYMOVIS.

HYMOVIS is indicated for the treatment of pain associated with osteoarthritis and the improvement of joint mobility by increasing the viscoelasticity of the synovial fluid.

Do not use the product in patients with known individual hypersensitivity to its components and in the case of infections or skin diseases in the vicinity of the injection site.